Recent News

523 News Items found
Alexander Rudensky
An Interview With Alexander Rudensky
A member of the Sloan Kettering Institute's Immunology Program and a Howard Hughes Medical Institute investigator, Alexander Rudensky is fascinated by how a specific type of white blood cells called regulatory T cells regulates our immune system.
Samuel Danishefsky
As part of a commitment to seek new and better treatments for cancer patients, Memorial Sloan Kettering Cancer Center and Bristol-Myers Squibb are collaborating to bring a potential new cancer drug called iso-fludelone, or KOS-1803, into clinical trials.
Pictured: Eric C. Holland
A multi-institutional team led by investigators from Memorial Sloan Kettering Cancer Center has published a study that provides new insight into genetic changes that make some forms of glioblastoma, the most common type of primary brain cancer, more aggressive than others and explains why they may not respond to certain therapies.
A multicenter study led by Memorial Sloan Kettering researchers has answered an important question about the safety of using carbon nanotubes in medicine.
Boris Bastian
Physician-scientist Boris C. Bastian joined Memorial Sloan Kettering as Attending Physician and Chair of the Department of Pathology on April 1.
Harold Varmus former CEO of MSK
Harold Varmus became President and Chief Executive Officer of Memorial Sloan Kettering Cancer Center on January 1, 2000. He ended his decade-long tenure on July 1, 2010. And on July 12, 2010, Dr. Varmus took up a new role as Director of the National Cancer Institute.
A team of Memorial Sloan Kettering researchers reports that prostate cancer often takes an aggressive course in patients who have inherited mutations in the genes BRCA1 or BRCA2.
Ingo Mellinghoff
A multicenter team led by Memorial Sloan Kettering neurologist and researcher Ingo K. Mellinghoff has uncovered the relationship between two proteins that play a critical role in glioblastoma, the most common form of brain cancer.
Charles Sawyers
A unique collaboration among physician-scientists at Memorial Sloan Kettering Cancer Center has yielded the most comprehensive genomic analysis of prostate cancer to date. The study, published in the journal Cancer Cell, provides a previously unavailable genomic analysis whose scope and size offers new insight leading to more effective diagnostic tests as well as future treatment options for prostate cancer patients.
Charles Sawyers
Charles L. Sawyers, Chair of the Human Oncology and Pathogenesis Program, was elected to the National Academy of Sciences at the group's 147th annual meeting in April.